Sign in

CIK 0001714899 · Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
463872213
Phone
(650) 866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Grant or award Director acquired 21,130 shares (grant or award)
  2. 3 Insider Initial Statement of Ownership
  3. 3 Insider Initial Statement of Ownership
  4. 4 Grant or award Director acquired 6,037 shares (grant or award)
  5. 4 Grant or award Director acquired 6,037 shares (grant or award)
  6. 4 Grant or award Director acquired 6,037 shares (grant or award)
  7. 4 Grant or award Director acquired 6,037 shares (grant or award)
  8. 4 Grant or award Director acquired 6,037 shares (grant or award)
  9. 4 Grant or award Director acquired 6,037 shares (grant or award)
  10. 4 Grant or award Director acquired 6,037 shares (grant or award)
  11. 8-K Event Material agreement · Shareholder vote results
  12. 10-Q Report Quarterly Report
  13. 8-K Event Results of operations
  14. ARS Other Annual Report to Security Holders
  15. DEFA14A Proxy Proxy Materials
  16. DEF 14A Proxy Proxy Statement
  17. SCHEDULE 13G/A Stake Statement of Beneficial Ownership
  18. 8-K Event Regulation FD disclosure
  19. 8-K Event Regulation FD disclosure
  20. S-8 Other Securities Offered to Employees in Benefit Plans

Page 5 of 40 · 789 filings